PDBsum entry 3f68

Hydrolase/hydrolase inhibitor

PDB id: 3f68

Contents

Protein chains

27 a.a. *

249 a.a. *

Ligands

ASP-PHE-GLU-GLU-ILE-PRO-GLU-GLU-TYS

91U

Metals

_NA ×2

Waters ×104

* Residue conservation analysis

PDB id:

3f68

Name:

Hydrolase/hydrolase inhibitor

Title:

Thrombin inhibition

Structure:

Prothrombin. Chain: l. Fragment: unp residues 328-363, thrombin light chain. Synonym: coagulation factor ii, activation peptide fragment 1, activation peptide fragment 2, thrombin light chain, thrombin heavy chain. Prothrombin. Chain: h. Fragment: unp residues 364-622, thrombin heavy chain.

Source:

Homo sapiens. Human. Organism_taxid: 9606. Synthetic: yes. Hirudo medicinalis. Organism_taxid: 6421. Other_details: synthetic fragment of hirudin from hirudo medicinalis

Resolution:

1.75Å R-factor: 0.211 R-free: 0.256

Authors:

B.Baum,A.Heine,G.Klebe

Key ref:

B.Baum et al. (2009). Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin. J Mol Biol, 391, 552-564. PubMed id: 19520086 DOI: 10.1016/j.jmb.2009.06.016

Date:

05-Nov-08 Release date: 20-Oct-09

Protein chain

P00734  (THRB_HUMAN) -  Prothrombin from Homo sapiens

Seq: 622 a.a.

Struc: 27 a.a.

Protein chain

P00734  (THRB_HUMAN) -  Prothrombin from Homo sapiens

Seq: 622 a.a.

Struc: 249 a.a.

Enzyme reactions

• Enzyme class: Chains L, H: E.C.3.4.21.5 - thrombin.
• Reaction: Preferential cleavage: Arg-|-Gly; activates fibrinogen to fibrin and releases fibrinopeptide A and B.

DOI no: 10.1016/j.jmb.2009.06.016

J Mol Biol 391:552-564 (2009)

PubMed id: 19520086

Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.

B.Baum, L.Muley, A.Heine, M.Smolinski, D.Hangauer, G.Klebe.

ABSTRACT

Successful design of potent and selective protein inhibitors, in terms of structure-based drug design, strongly relies on the correct understanding of the molecular features determining the ligand binding to the target protein. We present a case study of serine protease inhibitors with a bis(phenyl)methane moiety binding into the S3 pocket. These inhibitors bind with remarkable potency to the active site of thrombin, the blood coagulation factor IIa. A combination of X-ray crystallography and isothermal titration calorimetry provides conclusive insights into the driving forces responsible for the surprisingly high potency of these inhibitors. Analysis of six well-resolved crystal structures (resolution 1.58-2.25 A) along with the thermodynamic data allows an explanation of the tight binding of the bis(phenyl)methane inhibitors. Interestingly, the two phenyl rings contribute to binding affinity for very different reasons - a fact that can only be elucidated by a structure-based approach. The first phenyl moiety occupies the hydrophobic S3 pocket, resulting in a mainly entropic advantage of binding. This observation is based on the displacement of structural water molecules from the S3 pocket that are observed in complexes with inhibitors that do not bind in the S3 pocket. The same classic hydrophobic effect cannot explain the enhanced binding affinity resulting from the attachment of the second, more solvent-exposed phenyl ring. For the bis(phenyl)methane inhibitors, an observed adaptive rotation of a glutamate residue adjacent to the S3 binding pocket attracted our attention. The rotation of this glutamate into salt-bridging distance with a lysine moiety correlates with an enhanced enthalpic contribution to binding for these highly potent thrombin binders. This explanation for the magnitude of the attractive force is confirmed by data retrieved by a Relibase search of several thrombin-inhibitor complexes deposited in the Protein Data Bank exhibiting similar molecular features. Special attention was attributed to putative changes in the protonation states of the interaction partners. For this purpose, two analogous inhibitors differing mainly in their potential to change the protonation state of a hydrogen-bond donor functionality were compared. Buffer dependencies of the binding enthalpy associated with complex formation could be traced by isothermal titration calorimetry, which revealed, along with analysis of the crystal structures (resolution 1.60 and 1.75 A), that a virtually compensating proton interchange between enzyme, inhibitor and buffer is responsible for the observed buffer-independent thermodynamic signatures.

Selected figure(s)

Figure 1.
Fig. 1. Chemical formulas of inhibitors 1 to 6 discussed in this study. Inhibitory potency towards human thrombin is given as kinetic inhibition constant K[i] with the SD from averaging of at least three measurements. Relative differences of the thermodynamic properties between inhibitors, as indicated by the arrows, are given in kilojoules per mole.

Figure 2.
Fig. 2. Inhibitor 3 in complex with human thrombin blocked at the exosite by hirugen. (a) View of the active site, with solvent-accessible surface of thrombin's heavy chain in pale green, light chain in blue and hirugen in violet. Two refined sodium ions are shown as yellow spheres, water molecules as red spheres and the inhibitor skeleton in orange sticks; heteroatoms are color-coded. The F[o] − F[c] difference electron density for 3 is depicted in blue at 2.5σ. (b) Active-site residues are represented by green sticks; ligand 3 is shown in orange. The red sphere represents the water molecule being involved in a hydrogen-bonding network. Hydrogen bonds are indicated as broken lines in magenta.

The above figures are reprinted by permission from Elsevier: J Mol Biol (2009, 391, 552-564) copyright 2009.

Figures were selected by an automated process.